The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1305
Repetitive Transcranial Magnetic Stimulation (TMS) for Medication-Resistant Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has cleared a new device for treatment of major depressive disorder (MDD) resistant to antidepressant medication. The NeuroStar TMS System (Neuronetics) produces pulsed magnetic fields that can induce electrical currents in the brain. Unlike electroconvulsive therapy (ECT), it does not require anesthesia or induction of seizures. Other similar devices are under development

MECHANISM OF ACTION — A pulsed magnetic field from an insulated coil applied to the scalp produces an electrical current in the area of the brain under the coil, causing neuronal depolarization and other changes in brain activity that can be detected by positron emission tomography (PET) imaging. In the dorsolateral prefrontal cortex, these changes have been associated with improvement in the symptoms of depression.1

CLINICAL STUDIES — Among 301 patients with medication-refractory MDD ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Repetitive Transcranial Magnetic Stimulation (TMS) for Medication-Resistant Depression
Article code: 1305c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian